These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 514121)

  • 21. Activity of intraperitoneal heparin during peritoneal dialysis.
    Furman KI; Gomperts ED; Hockley J
    Clin Nephrol; 1978 Jan; 9(1):15-8. PubMed ID: 630740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of heparin during extracorporeal circulation in infants.
    Green TP; Isham-Schopf B; Irmiter RJ; Smith C; Uden DL; Steinhorn RH
    Clin Pharmacol Ther; 1990 Aug; 48(2):148-54. PubMed ID: 2379386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
    Schran HF; Bitz DW; DiSerio FJ; Hirsh J
    Thromb Res; 1983 Jul; 31(1):51-67. PubMed ID: 6612697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties.
    Holmer E; Söderberg K; Bergqvist D; Lindahl U
    Haemostasis; 1986; 16 Suppl 2():1-7. PubMed ID: 3744129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The appearance of donor heparin in the recipient after reperfusion of a liver graft.
    Bakker CM; Stibbe J; Gomes MJ; Groenland TN; Metselaar HJ; Hesselink EJ; Schalm SW; Terpstra OT
    Transplantation; 1993 Aug; 56(2):327-9. PubMed ID: 8356586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular distribution of intratracheally administered heparin.
    Mahadoo J; Hiebert LM; Wright CJ; Jaques LB
    Ann N Y Acad Sci; 1981; 370():650-5. PubMed ID: 7023328
    [No Abstract]   [Full Text] [Related]  

  • 27. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Hirsh J; Jay RM; Leclerc JR; Geerts WH; Rosenbloom D; Sackett DL; Anderson C; Harrison L
    N Engl J Med; 1986 Oct; 315(18):1109-14. PubMed ID: 3531862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catabolism of low-dose heparin in man.
    Dawes J; Papper DS
    Thromb Res; 1979; 14(6):845-60. PubMed ID: 473122
    [No Abstract]   [Full Text] [Related]  

  • 29. Anticoagulant activity and operative blood loss after intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Br J Surg; 1979 Dec; 66(12):844-7. PubMed ID: 509056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antithrombin III activity in relation to multiple administration of various doses of heparin to normal animals].
    Kudriashov BA; Pastorova VE; Liapina LA
    Vopr Med Khim; 1985; 31(3):37-41. PubMed ID: 4024529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The dynamics of the body distribution of heparin and its antagonist, the quaternary ammonium salt of conidine oligomer-25, when administered via the lungs].
    Rumiantsev AG; Golovleva OA; Rozkin MIa; Kazarian VA; Efimov VS
    Farmakol Toksikol; 1991; 54(1):49-51. PubMed ID: 1860499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of heparin. II. Studies of time dependence in rats.
    Bjornsson TD; Levy G
    J Pharmacol Exp Ther; 1979 Aug; 210(2):243-6. PubMed ID: 458631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraperitoneal heparin in CAPD.
    Gries E; Graben N; Bock KD; Paar D
    Life Support Syst; 1985; 3 Suppl 1():125-30. PubMed ID: 3870551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution and clearance of radioactive heparin.
    Effeney DJ; Case SA; Graziano C; Blaisdell FW
    Surg Forum; 1979; 30():198-9. PubMed ID: 538592
    [No Abstract]   [Full Text] [Related]  

  • 35. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
    Bratt G; Törnebohm E; Widlund L; Lockner D
    Thromb Res; 1986 Jun; 42(5):613-20. PubMed ID: 3715820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay.
    Dawes J; Prowse CV; Pepper DS
    Thromb Res; 1986 Dec; 44(5):683-93. PubMed ID: 2433788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Micromethod for the determination of heparin in plasma after intravenous and subcutaneous administration.
    Oreste P; Peruzzi M; Stella P
    Anal Biochem; 1993 Apr; 210(1):136-9. PubMed ID: 8489009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin via the lung.
    Wright CJ; Jaques LB
    Can J Surg; 1979 Jul; 22(4):317-9. PubMed ID: 455159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers.
    Kroon C; ten Hove WR; de Boer A; Kroon JM; van der Pol JM; Harthoorn-Lasthuizen EJ; Schoemaker HC; van der Meer FJ; Cohen AF
    Circulation; 1992 Nov; 86(5):1370-5. PubMed ID: 1423948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial sequestration of heparin administered by the intrapulmonary route.
    Mahadoo J; Hiebert LM; Jaques LB; Wright CJ
    Artery; 1980; 7(5):438-47. PubMed ID: 7213028
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.